a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies has submitted a conditional Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the companys lead Lm Technology product candidate, axalimogene filolisbac, for the treatment of adult women who progress beyond first-line therapy of persistent, recurrent or metastatic carcinoma
of the cervix (PRmCC).
Advaxis has submitted a conditional Marketing Authorization Application to the European Medicines Agency for the company's lead Lm Technology product candidate, axalimogene filolisbac, for the treatment of adult women who progress beyond first-line therapy of persistent, recurrent or metastatic carcinoma
of the cervix.
MVASI is the first biosimilar bevacizumab approved by the EC, and is approved in combination with fluoropyrimidine-based chemotherapy for metastatic carcinoma
of the colon or rectum; in combination with paclitaxel for metastatic breast cancer.
The company said MVASI is indicated for treatment of adult patients with metastatic carcinoma
of the colon or rectum, metastatic breast cancer; metastatic or recurrent NSCLC; metastatic or recurrent non-squamous NSCLC with (EGFR) activating mutations; metastatic renal cell cancer; advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer; as well as persistent, recurrent, or metastatic carcinoma
of the cervix.
Reactive hyperplasia, metastatic carcinoma
& lymphoma are more common in males.
6,7] Significant resource implications of the increasing use of the SLN biopsy technique require cost-effective and accurate protocols for the histological examination of the SLN for detection of metastatic carcinoma
1) The differential diagnosis of HCC versus metastatic carcinoma
is clinically important because prognosis and treatment approaches vary.
The association of the papillary metastatic carcinoma
and the thyroid nodule led us to suspect a primary thyroid tumor.
Lightfix clinical trial for the treatment of impending and pathologic fractures in the humerus due to metastatic carcinoma
In malignant lesions, Basal cell carcinoma has incidence of 4% and metastatic carcinoma
The topics include the anatomy and physiology of bone, skeletal manifestations of systematic disease, infections of bones and joints, metastatic carcinoma
in bone, diseases of synovial membrane, and managing orthopedic pathology specimens from the operating room to the microscope.
2860144) CBC News they are certain that this represents one of the earliest human cases of metastatic carcinoma